English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background: Glycemic variability (GV) has been identified as an important tool in the monitoring of type 1 diabetes mellitus (T1D), due to its ability to identify patients at greater risk of severe hypoglycemia and to constitute an independent risk factor for chronic complications of this disease. This study aimed to evaluate the GV pattern between individuals with T1D under different types of intensive treatment and the correlations of this GV with different clinical and biochemical variables. Methods: Volunteers with T1D (n=90) under different types of intensive treatment (NPH insulin, n=54; insulin glargine, n=19; and continuous subcutaneous insulin infusion (CSII) system, n=17) were analyzed in relation to glycemic control and GV. The glycated hemoglobin (HbA1c) and estimated average glucose (eAG) were used to estimate glycemic control. The daily average glucose (DAG) and its standard deviation (SDDAG) and coefficient of variability (CVDAG), as well the change in the levels of glycated hemoglobin (ΔHbA1c) were used to estimate GV. Results: Patients under CSII presented lower values of HbA1c, eAG, DAG, SDDAG and CVDAG than the other groups. DAG (median=189 mg/dL and IQR=157232) and SDDAG (median=89.8 mg/dL and IQR=72-111) correlated positively with HbA1c, with correlations coefficients of 0.67 and 0.64, respectively. Conclusions: The glycemic variability in patients with type 1 diabetes, even under intensive treatment, has a great amplitude, and has direct correlations with the classic parameters of disease control. DAG and SDDAG can be used in the short term as predictors of the glycated hemoglobin levels in order to allow directions and earlier adaptations in clinical management. *Correspondence to: Ricardo Rodrigues, Faculty of Medicine, Federal University of Uberlândia, MG, Brazil, E-mail: ricardo.rodrigues@ufu.br

How effective is the use of glycemic variability in the follow-up of type 1 diabetes under intensive care?